High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

PLoS Neglected Tropical Diseases

Volumn 8, Issue 12, 2014, Pages

  Alonso Padilla, Julio ^a   Rodríguez, Ana ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTITRICHOMONAL AGENT; BENZNIDAZOLE; BISOPROLOL; CARVEDILOL; E 1224; ML 341; NEU 321; NIFURTIMOX; POSACONAZOLE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PROTOZOAL DNA;

ALGORITHM; AMASTIGOTE; ARTICLE; CHAGAS DISEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); TRYPANOSOMA CRUZI; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HUMAN; MOUSE; PARASITOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; DNA, PROTOZOAN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; TRYPANOSOMA CRUZI;

EID: 84922212134     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003259     Document Type: Article

References (60)

1. Coura JR, Vinas PA, (2010) Chagas disease: a new worldwide challenge. Nature 465: S6–7.
2. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE, (2007) The challenges of Chagas Disease—grim outlook or glimmer of hope? PLoS Med 4: e332.
3. Hotez PJ DE, Woc-Colburn L, Serpa JA, Bezek S, et al. (2012) Chagas Disease: ‘The New HIV/AIDS of the Americas'. PLoS Negl Trop Dis 6: e1498.
4. Rassi A, JrRassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388–1402.
5. Wilkinson SR, Kelly JM, (2009) Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 11: e31.
6. WHO (2014) Chagas disease (American trypanosomiasis). Available: http://www.who.int/mediacentre/factsheets/fs340/en/. Accessed 10 November 2014.
7. Machado-de-Assis GF, Diniz GA, Montoya RA, Dias JC, Coura JR, et al. (2013) A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention. Mem Inst Oswaldo Cruz 108: 873–880.
8. Rodriguez-Guerineau L, Posfay-Barbe KM, Monsonis-Cabedo M, Juncosa-Morros T, Diana A, (2014) Pediatric Chagas disease in Europe: 45 cases from Spain and Switzerland. Pediatr Infect Dis J 33: 458–462.
9. Andrade MC, Oliveira Mde F, Nagao-Dias AT, Coêlho IC, Cândido Dda S, et al. (2013) Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study. Rev Soc Bras Med Trop 46: 776–778.
10. Bertocchi GL, Vigliano CA, Lococo BG, Petti MA, Viotti RJ, (2013) Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria. Trans R Soc Trop Med Hyg 107: 372–376.
11. Viotti R, Alarcón de Noya B, Araujo-Jorge T, Grijalva MJ, Guhl F, et al. (2014) Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother 58: 635–639.
12. Bustamante JM, Craft JM, Crowe BD, Ketchie SA, Tarleton RL, (2014) New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection on mice. J Infect Dis 209: 150–162.
13. Marin-Neto JA, Rassi A, JrMorillo CA, Avezum A, Connolly SJ, et at, (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of ethiological treatment in Chagas' cardiomyopathy: the benznidazole evaluation for interrupting trypanosomiasis (BENEFIT). Am Heart J 156: 37–43.
14. Bayer (2014) Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients. ClinicalTrials.gov identifier: NCT01927224. Available: http://clinicaltrials.gov/show/NCT01927224. Accessed 5 November 2014.
15. Hospital Universitari Vall d'Hebron Research Institute (2013) Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole (CHAGASAZOL). ClinicalTrials.gov identifier: NCT01162967. Available: http://clinicaltrials.gov/show/NCT01162967. Accessed 5 November 2014.
16. Merck Sharp & Dohme Corp. (2014) A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS). ClinicalTrials.gov identifier: NCT01377480. Available: http://clinicaltrials.gov/show/NCT01377480. Accessed 5 November 2014.
17. Drugs for Neglected Diseases (2014) Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease. ClinicalTrials.gov identifier: NCT01489228Available: http://clinicaltrials.gov/show/NCT01489228. Accessed 5 November 2014.
18. Martinelli M, Rassi A, JrMarin-Neto JA, de Paola AA, Berwanger O, et al. (2013) Chronic use of amiodarone against implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy: study rational and design of a randomized clinical trial. Am Heart J 166: 976–982.
19. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okondo DO, Oliveira BM, et al. (2007) A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 153: 544.e1–8.
20. Fundación Cardiovascular de Colombia (2010) Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity. ClinicalTrials.gov identifier: NCT00323973Available: http://clinicaltrials.gov/show/NCT00323973. Accessed 5 November 2014.
21. Urbina JA, (2009) Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104: 311–318.
22. Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, et al. (2010) Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 82: 583–587.
23. VandeBerg JL (2012) Treatment trials and efficacy determination in non-human primates with chronic T. cruzi infections. Chagas Drug Discovery Consortium (CDDC) 2012 Meeting. Available: https://sites.google.com/site/chagasddc/. Accessed 5 November 2014.
24. Molina I (2012) First clinical trial with posaconazole and benznidazole for the treatment of Chagas disease. International Congress of Tropical Medicine. Available: http://ictmm2012.ioc.fiocruz.br/program_25_sept.html. Accessed 5 November 2014.
25. DNDi (14 November 2013) Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy. Available: http://www.dndi.org/media-centre/press-releases/1700-e1224.html. Accessed 5 November 2014.
26. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC, (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40: 2592–2597.
27. Bettiol E, Samanovic M, Murkin AS, Raper J, Buckner F, et al. (2009) Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis 3: e384.
28. Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, et al. (2010) In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis 4: e740.
29. Rodriguez A, Tarleton RL, (2012) Transgenic parasites accelerate drug discovery. Trends Parasitol 28: 90–92.
30. Brodin P, Christophe T, (2011) High content screening in infectious diseases. Curr Opin Chem Biol 15: 534–539.
31. Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, et al. (2010) Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob Agents Chemother 54: 3326–3334.
32. Moon S, Siquiera-Neto JL, Moraes CB, Yang G, Kang M, et al. (2014) An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi. PLoS ONE 9(2): e87188.
33. Sykes ML, Avery VM, (2013) Approaches to protozoan drug discovery: phenotypic screening. J Med Chem 56: 7727–7740.
34. De Muylder G, Ang KK, Arkin MR, Engel JC, McKerrow JH, (2011) A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5: e1253.
35. Bustamante JM, Tarleton RL, (2011) Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov 6: 653–661.
36. Clayton J, (2010) Chagas disease: pushing through the pipeline. Nature 465: S12–15.
37. Taylor MC, Huang H, Kelly JM, (2011) Genetic techniques in Trypanosoma cruzi. Adv Parasitol 75: 231–250.
38. Hyland KV, Asfaw SH, Olson CL, Daniels MD, Engman DM, (2008) Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol 38: 1391–1400.
39. Carmody LC, Germain A, Barker D, Galan-Rodriguez C, Bettiol E, et al. (2010) Identification of Small-Molecule Inhibitors of Trypansoma cruzi Infection. In: (2010) Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda, MD: National Center for Biotechnology Information (US). Available: http://www.ncbi.nlm.nih.gov/books/NBK55071/. Accessed 10 November 2014.
40. Rodriguez A (2013) HTS for T. cruzi infection of mammalian cells through GSK-Open Lab. 62nd Annual Meeting of the American Society of Tropical Medicine and Hygene.[Abstract] Available: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3336&sKey=5789c358-2171-43ef-a40a-6bc1c5741e22&cKey=94f790cd-cc53-47e9-9e2e-7255bb58a6af&mKey=ceafe81a-9b33-4623-a1bb-85d31108b94b#. Accessed 5 November 2014.
41. Andriani G, Chessler AD, Courtemanche G, Burleigh BA, Rodriguez A, (2011) Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis 5: e1298.
42. Germain AR, Carmody LA, Dockendorff C, Galan-Rodriguez C, Rodriguez A, et al. (2011) Identification of small-molecule inhibitors of Trypanosoma cruzi replication. Bioorg Med Chem Lett 21: 7197–7200.
43. Broad Institute (2013) NIH/3T3 (mouse embryonic fibroblast) toxicity Measured in Cell-Based System Using Plate Reader - 2138-02_Inhibitor_Dose_DryPowder_Activity. PubChem BioAssay AID: 651844. Available: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=651844. Accessed 5 November 2014.
44. Andriani G, Amata E, Beatty J, Clements Z, Coffey BJ, et al. (2013) Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J Med Chem 56: 2556–2667.
45. Dandapani S, Germain AR, Jewett I, Le Quement S, Marie JC, et al. (2014) Diversity-oriented synthesis yields a new drug lead for treatment of Chagas disease. ACS Med Chem Lett 5(2): 149–153.
46. Zanella F, Lorens JB, Link W, (2010) High content screening: seeing is believing. Trends Biotechnol 28: 237–245.
47. Siqueira-Neto JL, Moon S, Jang J, Yang G, Lee C, et al. (2012) An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl Trop Dis 6: e1671.
48. Aulner N, Danckaert A, Rouault-Hardoin E, Desrivot J, Helynck O, et al. (2013) High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery. PLoS Negl Trop Dis 7: e2154.
49. De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, et al. (2013) Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother 57: 2913–2922.
50. Nohara LL, Lema C, Bader JO, Aguilera RJ, Almeida IC, (2010) High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi. Parasitol Int 59: 565–570.
51. Buchser W, Collins M, Garyantes T, Guha R, Haney S, et al. (2012) Assay development guidelines for image-based high content screening, high content analysis and high content imaging. Assay guidance manual Available: http://www.ncbi.nlm.nih.gov/books/NBK100913/. Accessed 5 November 2014.
52. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, et al. (2009) Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3: e440.
53. Jelicks LA, Tanowitz HB, (2011) Advances in imaging of animal models of Chagas disease. Adv Parasitol 75: 193–208.
54. Romanha AJ, Castro SL, Soeiro MdeN, Lannes-Vieira J, Ribeiro I, et al. (2010) In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz 105: 233–238.
55. Goyard S, Dutra PL, Deolindo P, Autherman D, D′Archivio S, et al. (2014) In vivo imaging of trypanosomes for a better assessment of host-parasite relationships and drug efficacy. Parasitol Int 63: 260–268.
56. Lewis MD, Fortes Francisco A, Taylor MC, Burrell-Saward H, McLathie AP, et al. (2014) Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disese in the absence of locally persistent infection. Cell Microbiol 16: 1285–1300 doi:11.1111/cmi.12297
57. Brune K, (2002) Animal experimentation in sciences: sadistic nonsense or indispensable necessity? ALTEX 19: 130–136.
58. http://ocs.med.nyu.edu/anti-infectives-screening
59. Bustamante JM, Bixby LM, Tarleton RL, (2008) Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 14: 542–550.
60. Bustamante JM, Park HJ, Tarleton RL, The Chagas Drug Discovery Consortium, (2011) Report of the 2nd Chagas drug discovery consortium meeting, held on November 2010; Atlanta GA, USA. Expert Opin Drug Discov 6: 965–973.